Davids MS et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood 2022;139(5):686-9. Abstract
Grever M et al. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia 2021;35(7):1864-72. Abstract
Khountham S et al. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2021;62(3):716-21. Abstract
Kuter DJ et al. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. Am J Hematol 2022;[Online ahead of print]. Abstract
Mato AR et al. Recognizing unmet need in the era of targeted therapy for CLL/SLL: “What’s past is prologue” (Shakespeare). Clin Cancer Res 2022;28(4):603-8. Abstract
Roeker LE et al. COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies. Blood 2021;138(18):1768-73. Abstract
Rogers KA et al. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2021;Abstract 4030.
Rogers KA et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2021;106(9):2364-73. Abstract
Rogers KA et al. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax. Curr Med Res Opin 2021;37(8):1409-20. Abstract
Siddiqi T et al. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: Pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma 2022:[Online ahead of print]. Abstract
Stephens DM et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: Outcomes from a large multi-center collaboration. Haematologica 2021;106(11):2845-52. Abstract
Woyach JA et al. Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. ASH 2021;Abstract 639.